海辰药业(300584) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 142,649,339.94, representing a 36.43% increase compared to CNY 104,561,855.22 in the same period last year[5] - Net profit attributable to shareholders was CNY 15,036,959.76, up 12.57% from CNY 13,357,813.44 year-on-year[5] - Basic earnings per share rose to CNY 0.1253, reflecting a 12.58% increase from CNY 0.1113 in the same quarter last year[5] - Total operating revenue for the current period reached ¥142,649,339.94, a significant increase of 36.4% compared to ¥104,561,855.22 in the previous period[19] - Net profit for the current period was ¥14,962,869.89, representing a 12.0% increase from ¥13,357,813.44 in the previous period[21] - Earnings per share (EPS) for the current period was ¥0.1253, compared to ¥0.1113 in the previous period, reflecting a growth of 11.4%[21] Cash Flow - The net cash flow from operating activities surged to CNY 43,159,301.39, a remarkable increase of 822.02% compared to CNY 4,680,974.46 in the previous year[5] - Cash generated from operating activities was ¥151,327,782.50, an increase from ¥110,487,507.44 in the previous period[23] - Net cash flow from operating activities was 43,159,301.39, a significant increase from 4,680,974.46 in the previous period, indicating strong operational performance[24] - Cash and cash equivalents at the end of the period reached CNY 51,240,749.34, marking a 157.82% increase from CNY 19,874,244.44 at the end of the previous year[10] - Cash and cash equivalents at the end of the period amounted to 51,240,749.34, up from 19,874,244.44, showing improved liquidity[25] - The company reported a net increase in cash and cash equivalents of 5,482,031.51, contrasting with a decrease of 26,947,843.71 in the previous period[25] Expenses - Sales expenses increased by 46.10% to CNY 56,390,082.47, attributed to enhanced market penetration and increased promotional efforts[9] - The company experienced a 109.87% rise in management expenses, totaling CNY 38,657,009.14, primarily due to increased market research costs[9] - Total operating costs amounted to ¥124,158,918.05, up 45.0% from ¥85,582,384.45 in the prior period[20] - Research and development expenses were ¥4,331,960.14, a decrease from ¥5,429,812.44 in the previous period, indicating a focus on cost management[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,479,220,603.58, a 1.00% increase from CNY 1,464,546,955.74 at the end of the previous year[5] - Current assets total CNY 339,881,407.21, down from CNY 357,153,809.21 at the beginning of the period[16] - The company's fixed assets increased to CNY 239,081,615.92 from CNY 211,895,926.40[16] - The total non-current assets amount to CNY 1,139,339,196.37, up from CNY 1,107,393,146.53[16] - Total liabilities amounted to ¥426,101,674.20, slightly down from ¥426,373,270.65 in the previous period[17] - The company’s total current liabilities were ¥335,985,022.95, slightly up from ¥335,350,592.19 in the previous period[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,335[12] - The largest shareholder, Mr. Cao Yuping, holds 42.08% of the shares, totaling 50,491,306 shares, with 4,000,000 shares pledged[12] - The second-largest shareholder, Ms. Jiang Xiaoqun, holds 9.98% of the shares, totaling 11,973,913 shares[12] - The company has a total of 62,465,219 shares held by the largest and second-largest shareholders combined, representing 52.05% of the total shares[13] - The company has a total of 12,622,827 unrestricted shares held by Mr. Cao Yuping[13] Investment Activities - Net cash flow from investment activities was -35,246,026.30, a decline from -29,319,647.03, indicating higher investment outflows[24] - The company’s total cash inflow from investment activities was 1,005,809.45, reflecting limited investment recovery[24] - The company’s cash outflow for purchasing fixed assets was 27,151,835.75, slightly down from 29,319,647.03, indicating a reduction in capital expenditures[24] Credit and Impairment - The company reported a 597.78% increase in credit impairment losses, amounting to CNY 1,437,594.09, mainly due to the reversal of bad debt provisions[10]